Abstract
Reports of T cell malignancies after CAR-T cell therapy should be investigated, but existing data from follow-up studies suggest a low risk compared with other cancer treatments.
MeSH terms
-
Cell- and Tissue-Based Therapy
-
Hematologic Neoplasms* / pathology
-
Humans
-
Immunotherapy, Adoptive / adverse effects
-
Lymphoma, B-Cell* / therapy
-
Receptors, Chimeric Antigen*
Substances
-
Receptors, Chimeric Antigen